In-depth analysis of "monitoring drug catalog" spread to enterprises and departments


Release time:

2019-07-03

 

On July 1, the first batch of national key monitoring and rational drug use catalogues, which have attracted much attention in the industry, were officially announced.

According to the requirements, all medical institutions should establish a key monitoring and rational drug use drug management system, and strengthen the whole process management of the clinical application of drugs in the catalogue. Further standardize the prescribing behavior of doctors, formulate medication guidelines or technical specifications for the drugs included in the catalog, and clearly stipulate the conditions and principles of clinical application. If there are relevant medication guidelines or guiding principles, they should be strictly implemented in accordance with the guidelines or principles. Conduct prescription review and prescription review for all drugs included in the catalog, and strengthen the publicity, feedback and utilization of prescription review results. For varieties with prominent unreasonable drug use problems, measures such as ranking notification, rectification within a time limit, and removal of the agency's drug supply catalog are taken to ensure rational drug use.

The clinical use of drugs included in the catalogue is taken as the assessment content of medical institutions and their main responsible persons, combined with the verification, evaluation and performance appraisal of medical institutions, and the assessment results are publicized in a timely manner.

The first batch of national key monitoring rational drug use drugs and domestic key city hospital sales (chemical drugs and biological products)

Data source: PDB Comprehensive Drug Database

According to data from the PDB, the comprehensive drug database of the China Pharmaceutical Industry Information Center, the sales of the first batch of national key monitored rational drug use drugs in 2018 were all over 100 million yuan, and the sales of oxiracetam, which ranked first, were nearly 1.5 billion.

In fact, since February 2015, the General Office of the State Council issued the ''Guiding Opinions on Improving the Centralized Procurement of Drugs in Public Hospitals'', proposing to focus on tracking and monitoring auxiliary drugs. Now the first batch of national key monitoring and rational drug use catalogues have been issued. The determination to attack and supervise auxiliary drugs is very obvious. Judging from the growth of drugs under the national key monitoring of rational drug use, most varieties have clearly felt the impact. In 2018, the growth rate of more than half was less than-20%, and even more than-60%.

In 2018, the state focused on monitoring the growth rate of rational drug use drug sales.

Data source: PDB Comprehensive Drug Database

The RAS database of China Pharmaceutical Industry Information Center has also supported the analysis data of drug use in clinical departments in Shanghai. In the past two years, the proportion of drugs in the control fee has decreased year by year, and the prescription amount of these monitored varieties has decreased significantly, and good results have been achieved.

In the past two years, the state has focused on monitoring the change rate of the amount of drug prescriptions for rational drug use.

Data source: hospital prescription analysis system RAS database

From the analysis of the field of treatment, the 20 drugs under national key monitoring are mainly concentrated in the nervous system drugs and cardiovascular system drugs.

The first batch of national key monitoring of the main distribution areas of rational drug use

Data source: PDB Comprehensive Drug Database

The first batch of national key monitoring drugs for rational use of drugs affected a wide range of enterprises, with more than 10 approvals for more than half of the varieties, such as Qilu Pharmaceutical and Yangzijiang Pharmaceutical.

The first batch of national key monitoring drug approval for rational drug use

Data source: PDB Comprehensive Drug Database

The manufacturers with the largest market share of each drug are shown in the table below.

The first batch of national key monitoring of rational drug use of major drug manufacturers

Data source: PDB Comprehensive Drug Database

Further analysis of the flow direction of the first batch of national key monitoring departments for rational drug use is shown in the following table.

Distribution of the first batch of national key monitoring of rational drug use in major departments